The role of oxidative stress and haematological parameters in relapsing-remitting multiple sclerosis in Kurdish population

Rasoul, Abdulrahman Aziz; Khudhur, Zhikal Omar; Hamad, Majeed Salih; Ismaeal, Younis Sadiq; Smail, Shukur Wasman; Rasul, Mohammed Fatih; Mohammad, Karzan Abdulmuhsin; Bapir, Ahmed Abdulrazzaq; Omar, Shwan Ali; Qadir, Mahdi Khaled; Rajab, Mustafa Fahmi; Salihi, Abbas; Kaleem, Muhammad; Rizwan, Muhammad; Qureshi, Anas Sarwar; Iqbal, Zeeshan; Qudratullah,

doi:10.1016/j.msard.2021.103228

Cited by 5 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to International Advisory Committee on Clinical Trials of MS in 2013, based on the classification made by Lublin et al, four main clinical courses of the disease have been identified, depending on its evolution: relapsing-remitting type (RRMS), progressive relapsing type (PRMS), primary-progressive type (PPMS) and secondary-progressive type (SPMS) [179,180]. RRMS is reported to have the highest prevalence, being encountered in approximately 85% of cases [179].…”

Section: Cannabinoids and Multiple Sclerosismentioning

confidence: 99%

Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

Vasincu

Rusu

Ababei

et al. 2022

Biology

View full text Add to dashboard Cite

Neurodegenerative diseases are an increasing cause of global morbidity and mortality. They occur in the central nervous system (CNS) and lead to functional and mental impairment due to loss of neurons. Recent evidence highlights the link between neurodegenerative and inflammatory diseases of the CNS. These are typically associated with several neurological disorders. These diseases have fundamental differences regarding their underlying physiology and clinical manifestations, although there are aspects that overlap. The endocannabinoid system (ECS) is comprised of receptors (type-1 (CB1R) and type-2 (CB2R) cannabinoid-receptors, as well as transient receptor potential vanilloid 1 (TRPV1)), endogenous ligands and enzymes that synthesize and degrade endocannabinoids (ECBs). Recent studies revealed the involvement of the ECS in different pathological aspects of these neurodegenerative disorders. The present review will explore the roles of cannabinoid receptors (CBRs) and pharmacological agents that modulate CBRs or ECS activity with reference to Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD) and multiple sclerosis (MS).

show abstract

Section: Cannabinoids and Multiple Sclerosismentioning

confidence: 99%